Monte Rosa Therapeutics I... (GLUE)

NasdaqGS: GLUE · Real-Time Price · USD

13.38

-0.94 (-6.56%)

At close: Aug 28, 2026, 3:59 PM

13.38

+0.00%

After-hours: 7:30 PM

The price, the headline numbers and the latest news, in one place.

-6.56% (1D)

Bid	13.36
Market Cap	1.14B
Revenue (ttm)	28.73M
Net Income (ttm)	-161.12M
	1.53
	-1.75
	n/a
	-7.13
P/B (ttm)	2.34
P/S (ttm)	39.74
Earnings Date	Nov 5, 2026

Ask	17.6
Volume	884,550
Avg. Volume (20D)	1,428,406
Open	14.29
Previous Close	14.32
Day's Range	13.37 - 14.30
52-Week Range	4.60 - 25.77
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About GLUE

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflamma...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 24, 2021

Employees 173

Stock Exchange NasdaqGS

Ticker Symbol GLUE

Website https://www.monterosatx.com

Full Company Profile

Financial Performance

In 2025, Monte Rosa Therapeutics's revenue was 123.67M, an increase of 63.54% compared to the previous year's 75.62M. Earnings were -38.63M, a decrease of -46.87%.

Financial Statements

Earnings Surprise

Monte Rosa Therapeutics has released their quarterly earnings on Aug 6, 2026:

Revenue of $8.97M misses estimates by $0, with -61.33% YoY decline.
EPS of -0.43 misses estimates by -0.06, with -186.67% YoY decline.

Next Earnings Release

Monte Rosa Therapeutics Inc. is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade

News

3 weeks ago · Simply Wall St.

Monte Rosa Therapeutics (GLUE) Is Down 30.7% After Deepening Q2 Losses And H1 Earnings Reversal

Monte Rosa Therapeutics, Inc. recently reported second-quarter 2026 results showing a net loss of US$43.4 million, up from US$12.3 million a year earlier, with basic and diluted loss per share widenin...

3 weeks ago · Zacks

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates

Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of -72.00% and -65.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stoc...